Dose-escalation, phase I study in advanced solid tumors or lymphoma with homozygous MTAP deletion was realized and is now terminated due to changes in the study strategy (introduction of combination therapies instead of AG 270 monotherapy in subsequent studies). This evidence concerns the gene MTAP and lymphoma.